Pasar al contenido principal

COORDINACION Y COOPERACION DE CELULAS INMUNES DURANTE INFECCIONES VIRALES AGUDAS Y CRONICAS

PID2022-141395OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis

  • Casella, Valentina|||0000-0001-8197-6467
  • Cebollada Rica, Paula|||0000-0003-3246-7353
  • Argilaguet, Jordi|||0000-0001-5924-2774
  • Vidal Barba, Enric|||0000-0002-4965-3286
  • González-Cao, María|||0000-0003-3791-540X
  • Güerri-Fernández, Robert|||0000-0002-9794-9161
  • Bocharov, Gennady|||0000-0002-5049-0656
  • Meyerhans, Andreas|||0000-0003-0620-5317
Immunotherapy with checkpoint inhibitors, albeit commonly used against tumors, is still at its infancy against chronic virus infections. It relies on the reinvigoration of exhausted T lymphocytes to eliminate virus-infected cells. Since T cell exhaustion is a physiological process to reduce immunopathology, the reinvigoration of these cells might be associated with an augmentation of pathological changes. To test this possibility, we here analyzed in the model system of chronic lymphocytic choriomeningitis virus (LCMV)-infected mice whether treatment with the checkpoint inhibitor anti-PD-L1 antibody would increase CD8 T cell-dependent fibrosis. We show that pre-existing spleen fibrosis did not worsen under conditions that increase CD8 T cell functionality and reduce virus loads suggesting that the CD8 T cell functionality increase remained below its pathogenicity threshold. These promising findings should further encourage immunotherapeutic trials against chronic virus infections.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dynamics and sensitivity of the lifecycle of hepatitis B virus

  • Grebennikov, Dmitry
  • Sazonov, Igor
  • Savinkov, Rostislav
  • Zakharov, Matvey
  • Sorokin, Mark
  • Mokin, Yakov
  • Meyerhans, Andreas
  • Bocharov, Gennady A.
A detailed mathematical model has been developed for the dynamics of hepatitis B virus (HBV) infection in a single cell. It provides a platform for a better quantitative understanding of the biochemical kinetics of the HBV lifecycle. The model is used to study the sensitivity of virus growth, providing a clear ranking of intracellular virus replication processes with respect to their contribution to net viral production. The stochastic formulation of the model enables the quantification of the variability characteristics in viral production, the probability of productive infection and the secretion of protein- and genome-deficient viral particles. An essential difference in infection efficiency between deterministic and stochastic models has been revealed. For example, in the case of (Formula presented.), the mean value of the total number of mature virions released during the lifecycle of the infection in the stochastic model is 1.06, whereas, in the deterministic model, its value is less than one thousandth and thus close to 0. The model is also used to quantitatively predict the effect of combinations of direct-acting antivirals, such as small interfering RNAs, capsid inhibitors and nucleoside analogues. The model shows that the inhibitory effect of siRNA on viral production is approximately two orders of magnitude higher than that of nucleoside analogues and capsid inhibitors., This research was funded by the Russian Science Foundation (Grant Number 23-11-00116) (deterministic model development, calibration and simulations presented in Section 1, Section 2.1, Section 2.2, Section 2.3, Section 2.4, Section 2.5, Section 3.1, Section 3.5 and Section 4). A.M. is also supported by Grant PID2022-141395OB-I00, funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU, and the 2021 SGR 00176 grant from the Departament de Recerca i Universitats de la Generalitat de Catalunya and "Unidad de Excelencia María de Maeztu" CEX2024-001431-M, funded by MICIU/AEI/10.13039/501100011033. The study was partly supported by the Moscow Center of Fundamental and Applied Mathematics at INM RAS (Agreement with the Ministry of Education and Science of the Russian Federation No. 075-15-2025-347) (stochastic model development and numerical simulations presented in Section 2.6, Section 3.2, Section 3.3 and Section 3.4).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Differential kinetics of splenic CD169+ macrophage death is one underlying cause of virus infection fate regulation

  • Casella, Valentina, 1991-
  • Domenjó Vila, Eva, 1993-
  • Esteve-Codina, Anna
  • Pedragosa Marín, Mireia, 1988-
  • Cebollada Rica, Paula
  • Vidal Barba, Enric
  • Rubia, Ivan de la
  • López Rodríguez, M. Cristina
  • Bocharov, Gennady A.
  • Argilaguet Marqués, Jordi, 1977-
  • Meyerhans, Andreas
Acute infection and chronic infection are the two most common fates of pathogenic virus infections. While several factors that contribute to these fates are described, the critical control points and the mechanisms that underlie infection fate regulation are incompletely understood. Using the acute and chronic lymphocytic choriomeningitis virus (LCMV) infection model of mice, we find that the early dynamic pattern of the IFN-I response is a differentiating trait between both infection fates. Acute-infected mice generate a 2-wave IFN-I response while chronic-infected mice generate only a 1-wave response. The underlying cause is a temporal difference in CD8 T cell-mediated killing of splenic marginal zone CD169+ macrophages. It occurs later in acute infection and thus enables CD169+ marginal zone macrophages to produce the 2nd IFN-I wave. This is required for subsequent immune events including induction of inflammatory macrophages, generation of effector CD8+ T cells and virus clearance. Importantly, these benefits come at a cost for the host in the form of spleen fibrosis. Due to an earlier marginal zone destruction, these ordered immune events are deregulated in chronic infection. Our findings demonstrate the critical importance of kinetically well-coordinated sequential immune events for acute infection control and highlights that it may come at a cost for the host organism., This work was supported by grants from the Spanish Ministry of Science and Innovation grant No. PID2019-106323RB-I00 AEI//10.13039/501100011033 and PID2022-141395OB-I00, the “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), the Russian Science Foundation grant No. 23-11-00116 and the AEC funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination

  • Sisteré-Oró, Marta
  • Du, Juan
  • Wortmann, Diana D. J.
  • Filippi, Marina D.
  • Cañas-Ruano, Esperanza
  • Arrieta Aldea, Itziar
  • Marcos-Blanco, Agustín
  • Castells, Xavier
  • Grau Cerrato, Santiago
  • Garcia Giralt, Natàlia
  • Perez-Zsolt, Daniel
  • Boreika, Rytis
  • Izquierdo-Useros, Nuria
  • Güerri Fernández, Roberto
  • Meyerhans, Andreas
People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan-pox-specific T-cell responses in a cohort of HIV-1-infected individuals after receiving the nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination was safe without major side effects. Dose-sparing i.d. vaccination was superior to s.c. vaccination and promoted T-cell polyfunctionality, and the expression of the gut-homing marker α4β7 integrin on lymphocytes. HIV-1-infected individuals with CD4 T-cell counts ≤500/mm3 blood required at least a booster vaccination to exhibit efficient virus-specific T-cell responses. The magnitude of the Th1 response after this booster directly correlated with the CD4 T-cell count of the vaccinees. Further studies with a larger number of participants are warranted to confirm and expand our observations., This work received support and funding from Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (grant number CB16/10/00245), Centro de Investigación Biomédica en Red Enfermedades Infecciosas, CIBERINFEC (CB21/13/00002), FEDER funds, FIS Project “PI19/00019” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, the Spanish Ministry of Science and Innovation grant number PID2022-141395OB-I00, and the “Unidad de Excelencia María de Maeztu,” funded by the MCIN and the AEI (DOI: 10.13039/501100011033). Nuria Izquierdo-Useros is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Quantifying the inhibitory efficacy of HIV-1 therapeutic interfering particles at a single CD4 T-cell resolution

  • Sazonov, Igor
  • Grebennikov, Dmitry
  • Savinkov, Rostislav
  • Meyerhans, Andreas
  • Bocharov, Gennady A.
Efficient control of HIV-1 infection relies on highly active antiretroviral therapy (HAART). However, this therapy is not curative and requires continuous drug administration. Application of HIV-1 defective interfering particles (DIPs), engineered with ablations in key viral protein expressions (e.g., Tat, Rev, Vpu, and Env), suggests a therapeutic potential transforming them into Therapeutic Interfering Particles (TIPs). A recent animal HIV model study in non-human primates reports a substantial reduction in viral load after a single intravenous injection of TIPs. In contrast, human clinical trials demonstrate no beneficial effect of defective interfering particles (DIPs) in people living with HIV-1. This discrepancy highlights the importance of further investigation of HIV-TIP interactions. A quantitative view of intracellular replication for HIV-1 in the presence of TIPs is still missing. Here, we develop a high-resolution mathematical model to study various aspects of the interference of a specific engineered TIP-2 particle characterized by a 2.5-kb deletion in the HIV pol-vpr region with HIV-1 replication within infected CD4+ T cells. We define the conditions in terms of the number of homozygous HIV-1 virions and TIP-2 particles that enable the reduction of the wild-type virus replication number to the value of about one. The deterministic model predicts that at a ratio of 1 HIV-1 to 10 TIP-2 particles, the infected cell still produces some viruses, although in a minor quantity, i.e., about two virions per cycle. Pre-activation of the interferon type I (IFN-I) system results in a complete block of HIV-1 production by TIP-2 co-infected cells. Overall, the modelling results suggest that to improve the effectiveness of TIPs in reducing HIV infection, their combination with other types of antiviral protection should be considered. Our results can be used in the development of combination therapy aimed at treating HIV-1 infection., This research was funded by the Russian Science Foundation (Grant Number 23-11-00116) (deterministic model development, calibration, and simulations presented in Sections Section 1, Section 2.1, Section 2.2, Section 2.3, Section 3.1, Section 3.2 and Section 4). A.M. is also supported by Grant PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU, the 2021 SGR 00176 grant from the Departament de Recerca i Universitats de la Generalitat de Catalunya, and "Unidad de Excelencia María de Maeztu" CEX2024-001431-M, funded by MICIU/AEI/10.13039/501100011033. The study was partly supported by the Moscow Center of Fundamental and Applied Mathematics at INM RAS (Agreement with the Ministry of Education and Science of the Russian Federation No. 075-15-2025-347) (stochastic model development and numerical simulations presented in Section 2.4, Section 3.4, Section 3.5, Section 3.6, Section 3.7 and Section 3.8).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Anti-PD-L1 immunotherapy of chronic virus infection improves virus control without augmenting tissue damage by fibrosis

  • Casella, Valentina, 1991-
  • Cebollada Rica, Paula
  • Argilaguet Marqués, Jordi, 1977-
  • Vidal Barba, Enric
  • González Cao, María
  • Güerri Fernández, Roberto
  • Bocharov, Gennady A.
  • Meyerhans, Andreas
Immunotherapy with checkpoint inhibitors, albeit commonly used against tumors, is still at its infancy against chronic virus infections. It relies on the reinvigoration of exhausted T lymphocytes to eliminate virus-infected cells. Since T cell exhaustion is a physiological process to reduce immunopathology, the reinvigoration of these cells might be associated with an augmentation of pathological changes. To test this possibility, we here analyzed in the model system of chronic lymphocytic choriomeningitis virus (LCMV)-infected mice whether treatment with the checkpoint inhibitor anti-PD-L1 antibody would increase CD8 T cell-dependent fibrosis. We show that pre-existing spleen fibrosis did not worsen under conditions that increase CD8 T cell functionality and reduce virus loads suggesting that the CD8 T cell functionality increase remained below its pathogenicity threshold. These promising findings should further encourage immunotherapeutic trials against chronic virus infections., This work was supported by grants PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU A way of making Europe, HR17-00199 from the ‘‘la Caixa’’ Foundation and the Russian Science Foundation grant No. 23-11-00116.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Lessons from the European mpox outbreak: strengthening cohort research for future pandemic preparedness

  • Visentin, Alessandro
  • Nazeri, Alessandra
  • Peñalvo, José Luis
  • Gorska, Anna
  • Davis, Ruth Joanna
  • Flett, Rosanna Louise
  • Simensen, Victoria Charlotte
  • Langeland, Nina
  • Gaday, Quentin
  • Mirandola, Massimo
  • Mazzotta, Valentina
  • Luong Nguyen, Liem Binh
  • Mothe, Beatriz
  • Van Dijck, Christophe
  • Meyerhans, Andreas
  • Boesecke, Christoph
  • Giaquinto, Carlo
  • Judd, Ali
  • Tacconelli, Evelina
Background: Well-designed cohort studies are crucial for pandemic preparedness, informing evidence-based infection prevention and treatment strategies. Objectives: Following the 2022 mpox outbreak in Europe, this scoping review critically evaluates the design, implementation, and characteristics of cohort studies focusing on mpox. The aim is to inform recommendations for the Cohort Coordination Board and the COordination MEchanism for Cohorts and Trials (CoMeCT) to enhance cohort study research and improve preparedness. Sources: A comprehensive literature search was conducted in PubMed, Scopus, ClinicalTrials.gov, the European Union Clinical Trials Register, and the European Clinical Research Infrastructure Network (ECRIN) metadata repository up to December 2024. Content: Forty-nine cohorts were identified, encompassing 10 728 individuals with primary or breakthrough mpox and 34 010 individuals without mpox (vaccinated and unvaccinated). The majority of cohorts collected data prospectively (30, 63%) and were multicentre (25, 52%). The primary aims were the natural history of mpox (31, 65%); effectiveness of vaccination (15, 31%); and treatment (2, 4%). The most frequent target population was individuals at increased risk of sexually transmitted infection (18, 38%). Follow-up of participants varied widely among cohorts. Significant data heterogeneity, stemming from the inconsistent use of standardized data dictionaries, impeded data sharing and meta-analyses. Under-representation of vulnerable populations and limited biobanking further compounded these challenges. Implications: This review underscores critical gaps in the research response during the mpox outbreak. Based on these findings, we propose the following recommendations: (1) establishing and maintaining "ever-warm" cohorts of high-risk individuals during inter-epidemic periods to enable rapid data collection during future outbreaks; (2) promoting data interoperability through the development and adoption of standardized data collection tools and ontologies; (3) improving the quality of study reporting through strict adherence to relevant guidelines; and (4) strengthening European and global coordination through the establishment of collaborative research networks. Sustained investment in research infrastructure is essential for a more effective, equitable, and timely public health response to future outbreaks., A.G. reported salary grants from VERDI and CoMeCT (101045989 and 101136531), A.J. reported EU funding to her institution (101045989 and 101136531), A.M. reported institutional grants funding his research activities (PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU and SGR00176 grant from the Departament de Recerca i Universitats de la Generalitat de Catalunya), A.N. reported salary grant from VERDI (101045989), C.B. reported grants from DZIF, NEAT-ID, DFG as well as consulting fees, honoraria and support for attending meetings and for travel from Abbvie, Gilead, JnJ, MSD, and ViiV and a leadership role in EACS, C.V.D. reported salary grant nr. 12B1M24N from Research Fund - Flanders (FWO), Q.G. reported grants and contracts from Institut Pasteur (ANR-18-CE11-0017 and ANR-21-CE11-0003) as well as CoMeCT (101136531). All other authors declare no conflict of interest.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Challenges in the vaccination of HIV-infected individuals

  • Sisteré-Oró, Marta
  • Güerri Fernández, Roberto
  • Plana, Montserrat
  • Bocharov, Gennady A.
  • Meyerhans, Andreas
Vaccination of people living with an HIV infection (PLWH) remains a worldwide challenge. The reason is the heterogeneity of this group that comprises people with and without highly active retroviral treatment and varying degrees of immunosuppression. In this review, we (i) highlight the impact of antiviral treatment success on vaccination outcomes, (ii) describe the current vaccine recommendations for PLWH, and (iii) summarize immunotherapeutic strategies for improved HIV immune control., This work was supported by Grant PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU, the 2021 SGR 00176 grant from the Departament de Recerca i Universitats de la Generalitat de Catalunya, and "Unidad de Excelencia María de Maeztu" CEX2024-001431-M, funded by MICIU/AEI/10.13039/501100011033 and the Russian Science Foundation (Grant Number 23-11-00116).
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Differential kinetics of splenic CD169+ macrophage death is one underlying cause of virus infection fate regulation

  • Casella, Valentina
  • Domenjo-Vila, Eva
  • Esteve-Codina, Anna
  • Pedragosa, Mireia
  • Cebollada Rica, Paula
  • Vidal, Enric
  • de la Rubia, Ivan
  • López-Rodríguez, Cristina
  • Bocharov, Gennady
  • Argilaguet, Jordi
  • Meyerhans, Andreas
Acute infection and chronic infection are the two most common fates of pathogenic virus infections. While several factors that contribute to these fates are described, the critical control points and the mechanisms that underlie infection fate regulation are incompletely understood. Using the acute and chronic lymphocytic choriomeningitis virus (LCMV) infection model of mice, we find that the early dynamic pattern of the IFN-I response is a differentiating trait between both infection fates. Acute-infected mice generate a 2-wave IFN-I response while chronic-infected mice generate only a 1-wave response. The underlying cause is a temporal difference in CD8 T cell-mediated killing of splenic marginal zone CD169+ macrophages. It occurs later in acute infection and thus enables CD169+ marginal zone macrophages to produce the 2nd IFN-I wave. This is required for subsequent immune events including induction of inflammatory macrophages, generation of effector CD8+ T cells and virus clearance. Importantly, these benefits come at a cost for the host in the form of spleen fibrosis. Due to an earlier marginal zone destruction, these ordered immune events are deregulated in chronic infection. Our findings demonstrate the critical importance of kinetically wellcoordinated sequential immune events for acute infection control and highlights that it may come at a cost for the host organism., We thank the Flow Cytometry and Genomic Core Facilities (Universitat Pompeu Fabra) and the Advanced Light Microscopy Unit (ALMU-CRG) for excellent technical support, Monica Perez (CReSA-IRTA-UAB) for helping with the histology samples and Hector Huerga Encabo (Immunology Unit, Universitat Pompeu Fabra) for fruitful discussions and ideas. We further thank Dr. Kenji Kohno and Dr. Masato Tanaka for allowing us to use their CD169-DTR transgenic mice which we obtained through Dr. Andres Hidalgo. The graphical abstract was created using BioRender.com platform. This work was supported by grants from the Spanish Ministry of Science and Innovation grant No. PID2019-106323RB-I00 AEI//10.13039/501100011033 and PID2022-141395OB-I00, the “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), the Russian Science Foundation grant No. 23-11-00116 and the AEC funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis

  • Casella, Valentina
  • Cebollada Rica, Paula
  • Argilaguet, Jordi
  • Vidal, Enric
  • González-Cao, María
  • Güerri-Fernandez, Roberto
  • Bocharov, Gennady
  • Meyerhans, Andreas
Immunotherapy with checkpoint inhibitors, albeit commonly used against tumors, is still at its infancy against chronic virus infections. It relies on the reinvigoration of exhausted T lymphocytes to eliminate virus-infected cells. Since T cell exhaustion is a physiological process to reduce immunopathology, the reinvigoration of these cells might be associated with an augmentation of pathological changes. To test this possibility, we here analyzed in the model system of chronic lymphocytic choriomeningitis virus (LCMV)-infected mice whether treatment with the checkpoint inhibitor anti-PD-L1 antibody would increase CD8 T cell-dependent fibrosis. We show that preexisting spleen fibrosis did not worsen under conditions that increase CD8 T cell functionality and reduce virus loads suggesting that the CD8 T cell functionality increase remained below its pathogenicity threshold. These promising findings should further encourage immunotherapeutic trials against chronic virus infections., This work was supported by grants PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/ 501100011033 and by ERDF/EU A way of making Europe, HR17-00199 from the “la Caixa” Foundation and the Russian Science Foundation grant No. 23-11-00116., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Differential kinetics of splenic CD169+ macrophage death is one underlying cause of virus infection fate regulation

  • Casella, Valentina
  • Domenjo-Vila, Eva
  • Esteve-Codina, Anna
  • Pedragosa, Mireia
  • Cebollada Rica, Paula
  • Vidal, Enric
  • de la Rubia, Ivan
  • López-Rodríguez, Cristina
  • Bocharov, Gennady
  • Argilaguet, Jordi
  • Meyerhans, Andreas
Acute infection and chronic infection are the two most common fates of pathogenic virus infections. While several factors that contribute to these fates are described, the critical control points and the mechanisms that underlie infection fate regulation are incompletely understood. Using the acute and chronic lymphocytic choriomeningitis virus (LCMV) infection model of mice, we find that the early dynamic pattern of the IFN-I response is a differentiating trait between both infection fates. Acute-infected mice generate a 2-wave IFN-I response while chronic-infected mice generate only a 1-wave response. The underlying cause is a temporal difference in CD8 T cell-mediated killing of splenic marginal zone CD169+ macrophages. It occurs later in acute infection and thus enables CD169+ marginal zone macrophages to produce the 2nd IFN-I wave. This is required for subsequent immune events including induction of inflammatory macrophages, generation of effector CD8+ T cells and virus clearance. Importantly, these benefits come at a cost for the host in the form of spleen fibrosis. Due to an earlier marginal zone destruction, these ordered immune events are deregulated in chronic infection. Our findings demonstrate the critical importance of kinetically wellcoordinated sequential immune events for acute infection control and highlights that it may come at a cost for the host organism., We thank the Flow Cytometry and Genomic Core Facilities (Universitat Pompeu Fabra) and the Advanced Light Microscopy Unit (ALMU-CRG) for excellent technical support, Monica Perez (CReSA-IRTA-UAB) for helping with the histology samples and Hector Huerga Encabo (Immunology Unit, Universitat Pompeu Fabra) for fruitful discussions and ideas. We further thank Dr. Kenji Kohno and Dr. Masato Tanaka for allowing us to use their CD169-DTR transgenic mice which we obtained through Dr. Andres Hidalgo. The graphical abstract was created using BioRender.com platform. This work was supported by grants from the Spanish Ministry of Science and Innovation grant No. PID2019-106323RB-I00 AEI//10.13039/501100011033 and PID2022-141395OB-I00, the “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), the Russian Science Foundation grant No. 23-11-00116 and the AEC funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lessons from the European mpox outbreak: strengthening cohort research for future pandemic preparedness

  • Visentin, Alessandro
  • Nazeri, Alessandra
  • Peñalvo, José Luis
  • Gorska, Anna
  • Davis, Ruth Joanna
  • Flett, Rosanna Louise
  • Simensen, Victoria Charlotte
  • Langeland, Nina
  • Gaday, Quentin
  • Mirandola, Massimo
  • Mazzotta, Valentina
  • Luong Nguyen, Liem Binh
  • Mothe, Beatriz
  • Van Dijck, Christophe
  • Meyerhans, Andreas
  • Boesecke, Christoph
  • Giaquinto, Carlo
  • Judd, Ali
  • Tacconelli, Evelina
Background: Well-designed cohort studies are crucial for pandemic preparedness, informing evidence-based infection prevention and treatment strategies. Objectives: Following the 2022 mpox outbreak in Europe, this scoping review critically evaluates the design, implementation, and characteristics of cohort studies focusing on mpox. The aim is to inform recommendations for the Cohort Coordination Board and the COordination MEchanism for Cohorts and Trials (CoMeCT) to enhance cohort study research and improve preparedness. Sources: A comprehensive literature search was conducted in PubMed, Scopus, ClinicalTrials.gov, the European Union Clinical Trials Register, and the European Clinical Research Infrastructure Network (ECRIN) metadata repository up to December 2024. Content: Forty-nine cohorts were identified, encompassing 10 728 individuals with primary or breakthrough mpox and 34 010 individuals without mpox (vaccinated and unvaccinated). The majority of cohorts collected data prospectively (30, 63%) and were multicentre (25, 52%). The primary aims were the natural history of mpox (31, 65%); effectiveness of vaccination (15, 31%); and treatment (2, 4%). The most frequent target population was individuals at increased risk of sexually transmitted infection (18, 38%). Follow-up of participants varied widely among cohorts. Significant data heterogeneity, stemming from the inconsistent use of standardized data dictionaries, impeded data sharing and meta-analyses. Under-representation of vulnerable populations and limited biobanking further compounded these challenges. Implications: This review underscores critical gaps in the research response during the mpox outbreak. Based on these findings, we propose the following recommendations: (1) establishing and maintaining "ever-warm" cohorts of high-risk individuals during inter-epidemic periods to enable rapid data collection during future outbreaks; (2) promoting data interoperability through the development and adoption of standardized data collection tools and ontologies; (3) improving the quality of study reporting through strict adherence to relevant guidelines; and (4) strengthening European and global coordination through the establishment of collaborative research networks. Sustained investment in research infrastructure is essential for a more effective, equitable, and timely public health response to future outbreaks., A.G. reported salary grants from VERDI and CoMeCT (101045989 and 101136531), A.J. reported EU funding to her institution (101045989 and 101136531), A.M. reported institutional grants funding his research activities (PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU and SGR00176 grant from the Departament de Recerca i Universitats de la Generalitat de Catalunya), A.N. reported salary grant from VERDI (101045989), C.B. reported grants from DZIF, NEAT-ID, DFG as well as consulting fees, honoraria and support for attending meetings and for travel from Abbvie, Gilead, JnJ, MSD, and ViiV and a leadership role in EACS, C.V.D. reported salary grant nr. 12B1M24N from Research Fund - Flanders (FWO), Q.G. reported grants and contracts from Institut Pasteur (ANR-18-CE11-0017 and ANR-21-CE11-0003) as well as CoMeCT (101136531). All other authors declare no conflict of interest.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Quantifying the inhibitory efficacy of HIV-1 therapeutic interfering particles at a single CD4 T-cell resolution

  • Sazonov, Igor
  • Grebennikov, Dmitry
  • Savinkov, Rostislav
  • Meyerhans, Andreas
  • Bocharov, Gennady A.
Efficient control of HIV-1 infection relies on highly active antiretroviral therapy (HAART). However, this therapy is not curative and requires continuous drug administration. Application of HIV-1 defective interfering particles (DIPs), engineered with ablations in key viral protein expressions (e.g., Tat, Rev, Vpu, and Env), suggests a therapeutic potential transforming them into Therapeutic Interfering Particles (TIPs). A recent animal HIV model study in non-human primates reports a substantial reduction in viral load after a single intravenous injection of TIPs. In contrast, human clinical trials demonstrate no beneficial effect of defective interfering particles (DIPs) in people living with HIV-1. This discrepancy highlights the importance of further investigation of HIV-TIP interactions. A quantitative view of intracellular replication for HIV-1 in the presence of TIPs is still missing. Here, we develop a high-resolution mathematical model to study various aspects of the interference of a specific engineered TIP-2 particle characterized by a 2.5-kb deletion in the HIV pol-vpr region with HIV-1 replication within infected CD4+ T cells. We define the conditions in terms of the number of homozygous HIV-1 virions and TIP-2 particles that enable the reduction of the wild-type virus replication number to the value of about one. The deterministic model predicts that at a ratio of 1 HIV-1 to 10 TIP-2 particles, the infected cell still produces some viruses, although in a minor quantity, i.e., about two virions per cycle. Pre-activation of the interferon type I (IFN-I) system results in a complete block of HIV-1 production by TIP-2 co-infected cells. Overall, the modelling results suggest that to improve the effectiveness of TIPs in reducing HIV infection, their combination with other types of antiviral protection should be considered. Our results can be used in the development of combination therapy aimed at treating HIV-1 infection., This research was funded by the Russian Science Foundation (Grant Number 23-11-00116) (deterministic model development, calibration, and simulations presented in Sections Section 1, Section 2.1, Section 2.2, Section 2.3, Section 3.1, Section 3.2 and Section 4). A.M. is also supported by Grant PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU, the 2021 SGR 00176 grant from the Departament de Recerca i Universitats de la Generalitat de Catalunya, and "Unidad de Excelencia María de Maeztu" CEX2024-001431-M, funded by MICIU/AEI/10.13039/501100011033. The study was partly supported by the Moscow Center of Fundamental and Applied Mathematics at INM RAS (Agreement with the Ministry of Education and Science of the Russian Federation No. 075-15-2025-347) (stochastic model development and numerical simulations presented in Section 2.4, Section 3.4, Section 3.5, Section 3.6, Section 3.7 and Section 3.8).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Anti-PD-L1 immunotherapy of chronic virus infection improves virus control without augmenting tissue damage by fibrosis

  • Casella, Valentina, 1991-
  • Cebollada Rica, Paula
  • Argilaguet Marqués, Jordi, 1977-
  • Vidal Barba, Enric
  • González Cao, María
  • Güerri Fernández, Roberto
  • Bocharov, Gennady A.
  • Meyerhans, Andreas
Immunotherapy with checkpoint inhibitors, albeit commonly used against tumors, is still at its infancy against chronic virus infections. It relies on the reinvigoration of exhausted T lymphocytes to eliminate virus-infected cells. Since T cell exhaustion is a physiological process to reduce immunopathology, the reinvigoration of these cells might be associated with an augmentation of pathological changes. To test this possibility, we here analyzed in the model system of chronic lymphocytic choriomeningitis virus (LCMV)-infected mice whether treatment with the checkpoint inhibitor anti-PD-L1 antibody would increase CD8 T cell-dependent fibrosis. We show that pre-existing spleen fibrosis did not worsen under conditions that increase CD8 T cell functionality and reduce virus loads suggesting that the CD8 T cell functionality increase remained below its pathogenicity threshold. These promising findings should further encourage immunotherapeutic trials against chronic virus infections., This work was supported by grants PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU A way of making Europe, HR17-00199 from the ‘‘la Caixa’’ Foundation and the Russian Science Foundation grant No. 23-11-00116.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Challenges in the vaccination of HIV-infected individuals

  • Sisteré-Oró, Marta
  • Güerri Fernández, Roberto
  • Plana, Montserrat
  • Bocharov, Gennady A.
  • Meyerhans, Andreas
Vaccination of people living with an HIV infection (PLWH) remains a worldwide challenge. The reason is the heterogeneity of this group that comprises people with and without highly active retroviral treatment and varying degrees of immunosuppression. In this review, we (i) highlight the impact of antiviral treatment success on vaccination outcomes, (ii) describe the current vaccine recommendations for PLWH, and (iii) summarize immunotherapeutic strategies for improved HIV immune control., This work was supported by Grant PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU, the 2021 SGR 00176 grant from the Departament de Recerca i Universitats de la Generalitat de Catalunya, and "Unidad de Excelencia María de Maeztu" CEX2024-001431-M, funded by MICIU/AEI/10.13039/501100011033 and the Russian Science Foundation (Grant Number 23-11-00116).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination

  • Sisteré-Oró, Marta
  • Du, Juan
  • Wortmann, Diana D. J.
  • Filippi, Marina D.
  • Cañas-Ruano, Esperanza
  • Arrieta Aldea, Itziar
  • Marcos-Blanco, Agustín
  • Castells, Xavier
  • Grau Cerrato, Santiago
  • Garcia Giralt, Natàlia
  • Perez-Zsolt, Daniel
  • Boreika, Rytis
  • Izquierdo-Useros, Nuria
  • Güerri Fernández, Roberto
  • Meyerhans, Andreas
People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan-pox-specific T-cell responses in a cohort of HIV-1-infected individuals after receiving the nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination was safe without major side effects. Dose-sparing i.d. vaccination was superior to s.c. vaccination and promoted T-cell polyfunctionality, and the expression of the gut-homing marker α4β7 integrin on lymphocytes. HIV-1-infected individuals with CD4 T-cell counts ≤500/mm3 blood required at least a booster vaccination to exhibit efficient virus-specific T-cell responses. The magnitude of the Th1 response after this booster directly correlated with the CD4 T-cell count of the vaccinees. Further studies with a larger number of participants are warranted to confirm and expand our observations., This work received support and funding from Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (grant number CB16/10/00245), Centro de Investigación Biomédica en Red Enfermedades Infecciosas, CIBERINFEC (CB21/13/00002), FEDER funds, FIS Project “PI19/00019” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, the Spanish Ministry of Science and Innovation grant number PID2022-141395OB-I00, and the “Unidad de Excelencia María de Maeztu,” funded by the MCIN and the AEI (DOI: 10.13039/501100011033). Nuria Izquierdo-Useros is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Differential kinetics of splenic CD169+ macrophage death is one underlying cause of virus infection fate regulation

  • Casella, Valentina, 1991-
  • Domenjó Vila, Eva, 1993-
  • Esteve-Codina, Anna
  • Pedragosa Marín, Mireia, 1988-
  • Cebollada Rica, Paula
  • Vidal Barba, Enric
  • Rubia, Ivan de la
  • López Rodríguez, M. Cristina
  • Bocharov, Gennady A.
  • Argilaguet Marqués, Jordi, 1977-
  • Meyerhans, Andreas
Acute infection and chronic infection are the two most common fates of pathogenic virus infections. While several factors that contribute to these fates are described, the critical control points and the mechanisms that underlie infection fate regulation are incompletely understood. Using the acute and chronic lymphocytic choriomeningitis virus (LCMV) infection model of mice, we find that the early dynamic pattern of the IFN-I response is a differentiating trait between both infection fates. Acute-infected mice generate a 2-wave IFN-I response while chronic-infected mice generate only a 1-wave response. The underlying cause is a temporal difference in CD8 T cell-mediated killing of splenic marginal zone CD169+ macrophages. It occurs later in acute infection and thus enables CD169+ marginal zone macrophages to produce the 2nd IFN-I wave. This is required for subsequent immune events including induction of inflammatory macrophages, generation of effector CD8+ T cells and virus clearance. Importantly, these benefits come at a cost for the host in the form of spleen fibrosis. Due to an earlier marginal zone destruction, these ordered immune events are deregulated in chronic infection. Our findings demonstrate the critical importance of kinetically well-coordinated sequential immune events for acute infection control and highlights that it may come at a cost for the host organism., This work was supported by grants from the Spanish Ministry of Science and Innovation grant No. PID2019-106323RB-I00 AEI//10.13039/501100011033 and PID2022-141395OB-I00, the “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), the Russian Science Foundation grant No. 23-11-00116 and the AEC funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis

  • Casella, Valentina
  • Cebollada Rica, Paula
  • Argilaguet, Jordi
  • Vidal, Enric
  • González-Cao, María
  • Güerri-Fernandez, Roberto
  • Bocharov, Gennady
  • Meyerhans, Andreas
Immunotherapy with checkpoint inhibitors, albeit commonly used against tumors, is still at its infancy against chronic virus infections. It relies on the reinvigoration of exhausted T lymphocytes to eliminate virus-infected cells. Since T cell exhaustion is a physiological process to reduce immunopathology, the reinvigoration of these cells might be associated with an augmentation of pathological changes. To test this possibility, we here analyzed in the model system of chronic lymphocytic choriomeningitis virus (LCMV)-infected mice whether treatment with the checkpoint inhibitor anti-PD-L1 antibody would increase CD8 T cell-dependent fibrosis. We show that preexisting spleen fibrosis did not worsen under conditions that increase CD8 T cell functionality and reduce virus loads suggesting that the CD8 T cell functionality increase remained below its pathogenicity threshold. These promising findings should further encourage immunotherapeutic trials against chronic virus infections., This work was supported by grants PID2022-141395OB-I00 funded by MICIU/AEI/10.13039/ 501100011033 and by ERDF/EU A way of making Europe, HR17-00199 from the “la Caixa” Foundation and the Russian Science Foundation grant No. 23-11-00116., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dynamics and sensitivity of the lifecycle of hepatitis B virus

  • Grebennikov, Dmitry
  • Sazonov, Igor
  • Savinkov, Rostislav
  • Zakharov, Matvey
  • Sorokin, Mark
  • Mokin, Yakov
  • Meyerhans, Andreas
  • Bocharov, Gennady A.
A detailed mathematical model has been developed for the dynamics of hepatitis B virus (HBV) infection in a single cell. It provides a platform for a better quantitative understanding of the biochemical kinetics of the HBV lifecycle. The model is used to study the sensitivity of virus growth, providing a clear ranking of intracellular virus replication processes with respect to their contribution to net viral production. The stochastic formulation of the model enables the quantification of the variability characteristics in viral production, the probability of productive infection and the secretion of protein- and genome-deficient viral particles. An essential difference in infection efficiency between deterministic and stochastic models has been revealed. For example, in the case of (Formula presented.), the mean value of the total number of mature virions released during the lifecycle of the infection in the stochastic model is 1.06, whereas, in the deterministic model, its value is less than one thousandth and thus close to 0. The model is also used to quantitatively predict the effect of combinations of direct-acting antivirals, such as small interfering RNAs, capsid inhibitors and nucleoside analogues. The model shows that the inhibitory effect of siRNA on viral production is approximately two orders of magnitude higher than that of nucleoside analogues and capsid inhibitors., This research was funded by the Russian Science Foundation (Grant Number 23-11-00116) (deterministic model development, calibration and simulations presented in Section 1, Section 2.1, Section 2.2, Section 2.3, Section 2.4, Section 2.5, Section 3.1, Section 3.5 and Section 4). A.M. is also supported by Grant PID2022-141395OB-I00, funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU, and the 2021 SGR 00176 grant from the Departament de Recerca i Universitats de la Generalitat de Catalunya and "Unidad de Excelencia María de Maeztu" CEX2024-001431-M, funded by MICIU/AEI/10.13039/501100011033. The study was partly supported by the Moscow Center of Fundamental and Applied Mathematics at INM RAS (Agreement with the Ministry of Education and Science of the Russian Federation No. 075-15-2025-347) (stochastic model development and numerical simulations presented in Section 2.6, Section 3.2, Section 3.3 and Section 3.4).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination

  • Sisteré-Oró, Marta|||0000-0003-0214-6348
  • Du, Juan
  • Wortmann, Diana D.J.
  • Filippi, Marina D.
  • Cañas-Ruano, Esperanza|||0000-0002-4651-7545
  • Arrieta-Aldea, Itziar
  • Marcos-Blanco, Agustín
  • Castells, Xavier|||0000-0002-2528-0382
  • Grau, Santiago|||0000-0002-8428-1836
  • Garcia-Giralt, Natalia|||0000-0001-6507-0147
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Boreika, Rytis|||0000-0001-6720-1577
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Güerri-Fernández, Robert|||0000-0002-9794-9161
  • Meyerhans, Andreas|||0000-0003-0620-5317
People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan-pox-specific T-cell responses in a cohort of HIV-1-infected individuals after receiving the nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination was safe without major side effects. Dose-sparing i.d. vaccination was superior to s.c. vaccination and promoted T-cell polyfunctionality, and the expression of the gut-homing marker α4β7 integrin on lymphocytes. HIV-1-infected individuals with CD4 T-cell counts ≤500/mm blood required at least a booster vaccination to exhibit efficient virus-specific T-cell responses. The magnitude of the Th1 response after this booster directly correlated with the CD4 T-cell count of the vaccinees. Further studies with a larger number of participants are warranted to confirm and expand our observations.